Abstract
Ponte Academic JournalAug 2022, Volume 78, Issue 8 DO HIGH PRE-OPERATIVE CA-125 LEVELS PREDICT EARLY RECURRENCE IN PATIENTS WITH HIGH-GRADE EPITHELIAL OVARIAN CANCER ?Author(s): Nilufer Bulut ,Tanju KapaganJ. Ponte - Aug 2022 - Volume 78 - Issue 8 doi: 10.21506/j.ponte.2022.8.8 Abstract:Background CA-125 is used as a marker in the diagnosis, treatment, and follow-up of ovarian cancers. High CA-125 levels indicate a high tumor burden, large ascites volume, and advanced stage. In the present study, the predictive value of CA-125 for the prognosis of ovarian cancer patients was determined. Materials-Methods The data of 173 patients diagnosed with ovarian cancer between 2009 and 2021 were analyzed retrospectively. CA-125 values before primary treatment were recorded. All patients underwent neoadjuvant chemotherapy or primary tumor surgery. Patients with normal CA-125 values at the end of treatment, and those with residual tumor, were followed up until the first recurrence. Disease-free and overall survival were analyzed. Results According to the preoperative CA-125 values, the disease-free survival time before treatment in patients with CA-125 levels of 0–40, 41–120, and > 121 U/ml was 73, 59.8, and 54 months, respectively; the differences were not statistically significant (p = 0.174). Patients with a ≥ 3-fold increase in their CA-125 value at recurrence had shorter overall survival (0–40 U/ml: 86 months; 41–120 U/ml: 60 months; > 121 U/ml: 54 months; p = 0.025). For patients without residual tumor after surgery, overall survival was 61 months, but it was significantly shorter (38 months) in those with residual tumor > 1 cm (p=0.001). Conclusion Levels of the tumor marker CA-125 are used to determine the response to treatment, residual tumor, and disease recurrence in ovarian cancer patients. Although elevated CA-125 levels alone do not contribute to the prognosis, patients with values 3-fold higher than before treatment had shorter overall survival. Download full text:Check if you have access through your login credentials or your institution Username Password
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
